Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8511676 | 0.89 | CNR1 (0.39) | CNR1CNR2 | |
| SCHEMBL899925 | 0.89 | CNR1 (0.39) | CNR1CNR2 | |
| SCHEMBL8509767 | 0.83 | — | — | |
| SCHEMBL899949 | 0.79 | NUDT1 (0.32) | — | |
| SCHEMBL900067 | 0.75 | — | — | |
| SCHEMBL899891 | 0.74 | NUDT1 (0.38) | — | |
| SCHEMBL8512605 | 0.74 | — | — | |
| SCHEMBL899419 | 0.74 | — | — | |
| SCHEMBL899845 | 0.73 | ESR1 (0.35) | — | |
| SCHEMBL1186506 | 0.69 | NUDT1 (0.44) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9261781-B2 | Preparation of norbornane-based PAC ballasts | SUMITOMO BAKELITE CO., LTD. (JP) | 2016-02-16 | — | — | US | claimed |
| US-20130323640-A1 | Preparation of Norbornane-based PAC Ballasts | SUMITOMO BAKELITE CO., LTD. (JP) | 2013-12-05 | — | — | US | claimed |
| US-9261781-B2 | Preparation of norbornane-based PAC ballasts | SUMITOMO BAKELITE CO., LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-20130323640-A1 | Preparation of Norbornane-based PAC Ballasts | SUMITOMO BAKELITE CO., LTD. (JP) | 2013-12-05 | — | — | US | disclosed |
| US-8530133-B2 | Preparation of norbornane-based PAC ballasts | PROMERUS, LLC (US) | 2013-09-10 | — | — | US | disclosed |
| EP-2622410-A1 | NORBORNANE-BASED PAC BALLAST AND POSITIVE-TONE PHOTOSENSITIVE RESIN COMPOSITION ENCOMPASSING THE PAC | Promerus, LLC (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20120135352-A1 | Preparation of Norbornane-based PAC Ballasts | PROMERUS LLC (US) | 2012-05-31 | — | — | US | disclosed |
| WO-2012044719-A1 | NORBORNANE-BASED PAC BALLAST AND POSITIVE-TONE PHOTOSENSITIVE RESIN COMPOSITION ENCOMPASSING THE PAC | PROMERUS LLC (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135352-A1 | Preparation of Norbornane-based PAC Ballasts | NBAS, PHB2, BDNF | CNR1 2967/4885CNR2 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.